AstraZeneca, Merck win quick OK for a rare disease drug — as the FDA declares it can still move fast during a crippling pandemic

Submitted by admin on April 11, 2020 - 11:05pm

Source:

Endpoints

News Tags:

AstraZenca

Merck

FDA

selumetinib

neurofibromatosis

Headline:

AstraZeneca, Merck win quick OK for a rare disease drug — as the FDA declares it can still move fast during a crippling pandemic

snippet:

On Friday, FDA oncology czar Richard Pazdur issued a special press release that noted regulators wasted no time in approving selumetinib from AstraZeneca and Merck, a proven treatment for neurofibromatosis type 1 — NF1 — a genetic disorder that triggers the growth of tumors on children’s nerves.

Search form

You are here

AstraZeneca, Merck win quick OK for a rare disease drug — as the FDA declares it can still move fast during a crippling pandemic

AstraZeneca, Merck win quick OK for a rare disease drug — as the FDA declares it can still move fast during a crippling pandemic